Brussels is hosting the European Forum for Industrial Biotechnology and Bioeconomy. Taking place on 9-11 October at SQUARE Brussels Meeting Centre, EFIB 2017 – organised by EuropaBio and Smithers Rapra – will take advantage of the opportunity to increase engagement between policy makers and a broad range of stakeholders connected with the existing bio-based value chain, and reach a new network of end users from a range of industries.
With themes ranging from inspiring new business models, circular economy and the creation of markets, to addressing the issues of ensuring financing and funding is available for commercialisation, in addition to the availability of feedstocks, this year’s EFIB agenda will provide a comprehensive update on the status and outlook of biobased industries.
Joanna Dupont-Inglis, Industrial Biotechnology Director at EuropaBio comments that there are many reasons for optimism in 2017. Momentum continues to build around the topic of biobased industries and Industrial Biotechnology is increasingly seen as a priority ‘Key Enabler’ of a more competitive and resource efficient circular bioeconomy. In parallel, Europe continues to see an increasingly high number of consumer brands, from automotive companies to sportswear, homecare, cosmetics and toy manufacturers, embracing the potential of new biobased materials. Reflecting this growing interest, companies such PepsiCo, Lego Group, Ikea, Renault, Unilever and L’Oréal will share their insights with the EFIB audience on the potential for higher use of biobased materials in the future.
Fast-moving consumer goods companies have also taken steps to embrace the circular economy and this hot topic will be addressed during the forum. While Industrial Biotechnology is currently estimated to be worth €28 billion in the EU, projections show that the EU market for IB products could develop to €40 billion by 2020 and up to €50 billion in 2050 with significant potential to become the dominant technology of Europe’s future chemicals industry.
The innovation tracks will ensure that crucial advancements in these technologies, processes and biomaterials are also given the chance to be showcased, with large players demonstrating their recent work in advancing industrial biotechnology across various end use sectors. Plus, SMEs have been given their own focus session, with Avantium, GFBiochemicals and more joining the agenda with new insights into platform chemicals, synthetic biology and sustainable chemistry solutions on the way to commercialisation.
EFIB 2017 is bringing the worlds of policy and business together to discuss how to boost investment, innovation and value chain development to capture the potential of white biotechnology in Europe.